TABLE 2.
Laboratory follow-up, hepatitis E virus (HEV) detection and treatment outcomes.
| Characteristics | Patient 1 | Patient 2 |
|---|---|---|
| Treatment start | December 2023 Ribavirin | December 2023 Ribavirin |
| Initial dose | 1,000 mg/day | 200 mg/day (renal adjustment) |
| Dose adjustment | 800 mg/day (hemolysis) | 400 mg/day (tolerance) |
| Further adjustment | 600 mg/day (hemolysis) | – |
| Month 0 | HEV RNA+(blood, stool) | HEV RNA+(blood, stool) |
| Month 1 | HEV RNA–(blood, stool) | HEV RNA–(blood, stool) |
| Month 2 | HEV RNA+(stool only) | HEV RNA+(stool only) |
| Month 3 | HEV RNA–(blood, stool) | HEV RNA–(blood, stool) |
| Month 6 | HEV RNA–(blood, stool) | HEV RNA–(blood, stool) |
| Month 3 post-treatment | HEV RNA–(blood, stool) | HEV RNA–(blood, stool) |
| Month 6 post-treatment | HEV RNA–(blood, stool) | HEV RNA–(blood, stool) |
| Adverse events | Hemolysis (Hb nadir 9.7 g/dL) | None |
| Outcome | Sustained virological clearance | Sustained virological clearance |